CSS Responds: Sources of Regional Variation in Medicare Part D Drug Spending, The New England Journal of Medicine

A recent NEJM study indicated nearly a two-fold difference between brand name drug use in low cost versus high cost regions (Donohue, et al, NEJM 366; 6). The Donohue study calculated that if all Medicare regions used brand name drugs in a manner similar to the lowest cost regions, the Medicare program could save approximately $4.5 billion in drug spend (~$11 million per Part D plan).

The Problem: The problem, as Donohue notes, is that using typical formulary tactics to eliminate brand drug use “…would deprive some patients of needed treatment options”.

The Solution: CSS’s iDeal Therapy is a focused medication management program that uses patients’ clinical features to identify and eliminate inappropriate brand drug use.

Let us know what you think?


James Notaro, RPh, PhD

More Recent Posts

  • Patient Acceptance of Pharmacist Run Transition of Care Service

    A recent article in Innovations in Pharmacy, describes a unique pharmacy based transition of care service. Kowalski et. al. describe … Continued

  • Are ACOs Prepared to Managed Medication Quality and Cost

    BACKGROUND Recentlt Wilks et. al published Optimization of Medication Use at Accountable Care Organizations.The authors studied accountable care organizations’ (ACO) … Continued

  • Integrating pharmacists into the patient centered medical home

    Recently Intermountain Healthcare (IH) reported on effort to integrate pharmacists in their patient centered medical home (PCMH).  IH is an … Continued

  • Request a Demo

    This is a basic introduction to MTMPath, our web-based MTM solution. We have a number of different modules to suit specific MTM needs. We will contact you to schedule an informational meeting after your introduction to MTMPathTM through our medication management software demo.